drugset / Trial / NCT00321997

A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

NCT00321997

Phase 2/3 Completed 540 enrolled Eyetech Pharmaceuticals Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in patients with wet AMD when compared to placebo injections.

Timeline

Start
2001-05
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer 0.3 mg Intravitreal